| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/26/2001 | WO2001029023A1 Benzopyranyl guanidine derivatives, process for preparation thereof, and pharmaceutical compositions containing them |
| 04/26/2001 | WO2001029022A1 Benzopyran derivatives |
| 04/26/2001 | WO2001029020A2 Neuraminidase inhibitors |
| 04/26/2001 | WO2001029018A2 Novel enantiomeric compounds for treatment of cardiac arrhythmias and methods of use |
| 04/26/2001 | WO2001029017A2 N-SUBSTITUTED 3-AMINO-2,2-DI-C-ALKYL-1,4-BUTYROLACTONES AND 1,4-THIOBUTYROLACTONES FOR USE AS PROMOTER OF η-AMINOBUTYRIC ACID ACTIVITY AND FOR TREATING NERVOUS DISORDERS AND PREPARATION METHOD |
| 04/26/2001 | WO2001029015A2 Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists |
| 04/26/2001 | WO2001029013A1 Process for preparing oxazolines from tetrahydrofurans |
| 04/26/2001 | WO2001029012A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 04/26/2001 | WO2001029011A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 04/26/2001 | WO2001029009A1 4,5-disubstituted-2-aminopyrimidines |
| 04/26/2001 | WO2001029007A1 Pyrazole derivatives as cannabinoid receptor antagonists |
| 04/26/2001 | WO2001029005A1 Bicyclic vasopressin agonists |
| 04/26/2001 | WO2001029000A2 Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| 04/26/2001 | WO2001028996A2 Pyrrolidine derivatives, their preparation and their use as inhibitors of neuraminidases |
| 04/26/2001 | WO2001028993A2 Tyrosine kinase inhibitors |
| 04/26/2001 | WO2001028992A2 New oxabispidine compounds useful in the treatment of cardiac arrhythmias |
| 04/26/2001 | WO2001028991A1 N-cycloalkyl thiooxamide derivatives |
| 04/26/2001 | WO2001028987A1 Benzylcycloalkyl amines as modulators of chemokine receptor activity |
| 04/26/2001 | WO2001028981A1 1-cyclohexene-1-carboxylic acid and 1-cyclohexene-1-carboxylates as neuraminidase inhibitors |
| 04/26/2001 | WO2001028979A2 Inhibitors of neuraminidases |
| 04/26/2001 | WO2001028978A1 Bicyclic amino acids as pharmaceutical agents |
| 04/26/2001 | WO2001028975A2 Method for production of 3-nitryloxy-2,2-bis(nitryloxymethyl)-propanal |
| 04/26/2001 | WO2001028973A1 Radical scavenger |
| 04/26/2001 | WO2001028616A1 Medicament pack |
| 04/26/2001 | WO2001028599A1 Isoalloxazine derivatives to neutralize biological contaminants |
| 04/26/2001 | WO2001028594A2 Tumor detection by imaging and therapy of tumors |
| 04/26/2001 | WO2001028592A1 Cobalamin conjugates useful as imaging agents and as antitumor agents |
| 04/26/2001 | WO2001028591A2 Injection vehicle for polymer-based formulations |
| 04/26/2001 | WO2001028589A2 Shaped body comprising an amphiphilic outer phase and a lipophilic inner phase |
| 04/26/2001 | WO2001028588A1 Cannabinoids as vasodilators and cardioprotectors against ischemia |
| 04/26/2001 | WO2001028587A2 Magnetic targeted carrier |
| 04/26/2001 | WO2001028580A2 Modulation of angiogenesis |
| 04/26/2001 | WO2001028579A2 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 04/26/2001 | WO2001028575A1 Proteoglycan, a bioactive substance from plants |
| 04/26/2001 | WO2001028571A1 Stable preparations for treating bedsore, skin ulcer and wound |
| 04/26/2001 | WO2001028570A2 Zinc lactate lozenges and uses thereof |
| 04/26/2001 | WO2001028569A1 Targeted vectors |
| 04/26/2001 | WO2001028568A1 Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase |
| 04/26/2001 | WO2001028567A2 Aminoalkylenephosphonates for treatment of bone disorders |
| 04/26/2001 | WO2001028566A1 Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia |
| 04/26/2001 | WO2001028565A1 Remedies for pigmentation and melanocyte proliferation inhibitors |
| 04/26/2001 | WO2001028564A1 Pharmaceutical compositions and preparations for treatment of metabolic bone disease |
| 04/26/2001 | WO2001028563A1 Ciclesonide-containing aqueous pharmaceutical composition |
| 04/26/2001 | WO2001028562A1 Ciclesonide contained pharmaceutical composition for application to mucosa |
| 04/26/2001 | WO2001028561A1 Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment |
| 04/26/2001 | WO2001028560A1 A new use of levosimendan |
| 04/26/2001 | WO2001028559A1 Method for stabilizing benzimidazole compounds |
| 04/26/2001 | WO2001028558A1 Formulation of substituted benzimidazoles |
| 04/26/2001 | WO2001028557A1 Cannabimimetic indole derivatives |
| 04/26/2001 | WO2001028556A2 Compositions for prevention and treatment of cold and influenza-like symptoms and their methods of use |
| 04/26/2001 | WO2001028555A1 Emulsion compositions for polyfunctional active ingredients |
| 04/26/2001 | WO2001028554A1 Treatment of attention deficit disorder and impaired visual-spatial function with androgen |
| 04/26/2001 | WO2001028553A1 Rivastigmine for the treatment of ocular disorders |
| 04/26/2001 | WO2001028552A2 Antimicrobial compositions comprising pyroglutamic acid and optionally metal salts |
| 04/26/2001 | WO2001028551A1 Agents for promoting fattening of animals and method of promoting fattening |
| 04/26/2001 | WO2001028550A1 Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia |
| 04/26/2001 | WO2001028549A1 Anti-ischemic compounds |
| 04/26/2001 | WO2001028548A1 Treatment of heart disease with cox-2 inhibitors |
| 04/26/2001 | WO2001028547A1 Food materials useful in preventing and ameliorating metabolic bone diseases and preventives/remedies for metabolic bone diseases comprising these materials |
| 04/26/2001 | WO2001028546A1 Inhibition of amyloidoses by using aromatic or heteroaromatic compounds substituted by electron-withdrawing groups |
| 04/26/2001 | WO2001028545A2 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 04/26/2001 | WO2001028544A2 Dialysis solution including polyglycol osmotic agent |
| 04/26/2001 | WO2001028543A1 TREATMENT OF EOSINOPHIL ASSOCIATED PATHOLOGIES BY MODULATING PKC-δ ACTIVITY |
| 04/26/2001 | WO2001028542A2 Combination therapy including camptothecin |
| 04/26/2001 | WO2001028541A2 Composition comprising sildenafil and l-arginine |
| 04/26/2001 | WO2001028540A2 Agent for treating cephalic pain |
| 04/26/2001 | WO2001028539A2 Agent for treating cephalic pain |
| 04/26/2001 | WO2001028538A2 Laxative preparation containing l-arginine |
| 04/26/2001 | WO2001028537A2 Bissulfonamide derivatives as enzyme inhibitors |
| 04/26/2001 | WO2001028535A2 Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate |
| 04/26/2001 | WO2001028534A2 Reduction moderators |
| 04/26/2001 | WO2001028533A2 PRODUCTS AND METHODS FOR ACTIVATING PPARη-RXR AND UP-REGULATING MONOCYTE/MACROPHAGE CD36 FOR THE TREATMENT OF MALARIA |
| 04/26/2001 | WO2001028532A2 Methods and compositions for predicting, diagnosing and treating lipodystrophy |
| 04/26/2001 | WO2001028531A1 Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin |
| 04/26/2001 | WO2001028530A1 Microcapsules for stabilizing cosmetic, pharmaceutical or food products |
| 04/26/2001 | WO2001028528A1 Methods, pharmaceutical and therapeutic compositions for administering adenosine |
| 04/26/2001 | WO2001028527A2 Direct compression polymer tablet core |
| 04/26/2001 | WO2001028523A1 Powder pharmaceutical formulations |
| 04/26/2001 | WO2001028522A2 Method for producing liposome preparation |
| 04/26/2001 | WO2001028521A2 Liposome formulation of 6,9-bis-[(2-aminoethyl)-amino]benzo[g]isoquinoline-5,10-dione dimaleate |
| 04/26/2001 | WO2001028517A1 Aqueous medicinal compositions |
| 04/26/2001 | WO2001028516A2 Sustained-release formulations for treating cns-mediated disorders |
| 04/26/2001 | WO2001028515A1 Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion |
| 04/26/2001 | WO2001028514A1 Pharmaceutical aerosol formulations comprising s-salmeterol |
| 04/26/2001 | WO2001028499A2 A therapeutic mixture of hmg-coa reductase inhibitors |
| 04/26/2001 | WO2001028498A2 Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| 04/26/2001 | WO2001028497A2 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 04/26/2001 | WO2001028494A2 Nordihydroguaiaretic derivatives for use in treatment of tumors |
| 04/26/2001 | WO2001028492A2 Polyanhydrides with biologically active degradation products |
| 04/26/2001 | WO2001028472A1 Drug delivery device |
| 04/26/2001 | WO2001028366A1 Composition for preventing iodine deficiency |
| 04/26/2001 | WO2001028365A1 Dietary supplement |
| 04/26/2001 | WO2001028363A1 Method for treatment of chronic venous insufficiencies using an extract of red vine leaves |
| 04/26/2001 | WO2001028356A2 Food supplement for increasing lean mass and strength |
| 04/26/2001 | WO2001028338A2 Antimicrobial compositions comprising a benzoic acid analog and a metal salt |
| 04/26/2001 | WO2001028337A2 Antiviral compositions for tissue paper |
| 04/26/2001 | WO2001006990A3 Use of etodolac to treat cancer |
| 04/26/2001 | WO2001005970A3 Gtp-binding protein associated factors |
| 04/26/2001 | WO2000075121A3 Process for preparing 10,11-methanobenzosuberane derivatives |
| 04/26/2001 | WO2000071723A3 Methods for regulating protein conformation using molecular chaperones |